Follow-up of patients with transthyretin amyloid cardiomyopathy by multi-modality imaging

• Conditions: E85; Amyloidosis

• Registration Number: DRKS00033884
• Lead Sponsor: Deutsches Herzzentrum der Charité

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-03-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.Diagnosed ATTR-CM according to current standards (TTE, DPD-scintigraphy and/or biopsy) AND:
2.Eligible to receive treatment with Tafamidis
3.Informed consent
4.Agrees to receive note about incidental findings
5.Valid health insurance

Exclusion Criteria

1.Non ATTR-CM
2.Severe cardiovascular comorbidities including:
a.Myocardial infarction within the last 6 months
b.After coronary stenting with in the last 6 month
c.After coronary artery bypass graft (CABG)
d.Permanent atrial fibrillation
3.Absolute contraindications for CMR
4.Allergy against gadolinium-containing contrast agent
5.Chronic kidney insufficiency with a GFR <30 ml/min
6.Pregnancy/Breastfeeding
7.No consent to study

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Therapy response to tafamidis. Secondarily identifying of quantitative imaging markers and comparing imaging modalities regarding the follow-up and prognostication of these patients.

Secondary Outcome Measures

Name	Time	Method
o classical endpoints.